AstraZeneca Seroquel Settlement With DoJ Leaves Door Open To Possible Criminal Claims
This article was originally published in The Pink Sheet Daily
AstraZeneca's $520 million civil settlement resolves allegations the company promoted Seroquel for off-label uses and provided kickbacks to doctors; DoJ reserves the right to pursue criminal liability claims.
You may also be interested in...
Budget proposal to fund state Medicaid programs through per capita cap or block grant would save $610bn over 10 years, administration says; budget calls for clarifying treatment of value-based pricing and fostering exchange of pre-approval information between manufacturers and payers.
Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.
Novartis still faces government investigations over its marketing of five other drugs; FDA issues a warning letter over its promotion of Gleevec on two company-sponsored websites.